Quote:

---

and given the work being done at MD Anderson, what do you think the possibility is of CytoDyn announcing a partnership in a trial of LL in combination with Keytruda PD-1 Inhibitor Pembrolizumab for mTNBC?

---

What we know is that maraviroc downregulates PD-L1 very well. Leronlimab with superior receptor occupancy would undoubtedly do even better. A PD-1 inhibitor would add little or nothing to the effect of leronlimab. There are other non-chemotherapy cancer drugs that could add benefit.